Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
Department of Intervention Radiology, Institute of Liver and Biliary Sciences, New Delhi, India.
Liver Int. 2022 Nov;42(11):2492-2500. doi: 10.1111/liv.15398. Epub 2022 Aug 25.
BACKGROUND & AIMS: This randomized controlled trial (RCT) was conducted with the aim to evaluate the efficacy and safety of using ROTEM-based transfusion strategy in cirrhotic children undergoing invasive procedures.
This was an open-label, RCT which included (i) children under 18 years of age with liver cirrhosis; (ii) INR between 1.5 and 2.5; and/or (iii) platelet count between 20 × 10 /L and 50 × 10 /L (for procedures other than liver biopsy) and between 40 × 10 /L and 60 × 10 /L (for liver biopsy); and (iv) listed for invasive procedures. Stratified randomization was done for children undergoing liver biopsies. Patients randomized to the ROTEM and conventional groups received blood component transfusion using predefined criteria.
A total of 423 invasive procedures were screened for inclusion of which 60 were randomized (30 in each group with comparable baseline parameters). The volume of total blood components, fresh frozen plasma (FFP) and platelets transfused was significantly lower in ROTEM as compared to conventional group. Only 46.7% of children in ROTEM group received a blood component compared to 100% in conventional group (p < .001). The requirement of FFP (ROTEM: 43.3%, Conventional: 83.3%, p = .001) was significantly lower in the patients receiving ROTEM-guided transfusions. There was no difference in procedure-related bleed and transfusion-related complications between the two groups. ROTEM was cost-effective (p = .002) despite the additional cost of the test.
ROTEM-based transfusion strategies result in lower blood component transfusion in cirrhotic children undergoing invasive procedures without an increase in risk of procedure-related bleed. ROTEM-guided transfusion strategy is cost-effective.
本随机对照试验(RCT)旨在评估基于 ROTEM 的输血策略在接受有创操作的肝硬化儿童中的疗效和安全性。
这是一项开放标签的 RCT,纳入标准为:(i)年龄<18 岁的肝硬化儿童;(ii)INR 在 1.5 至 2.5 之间;和/或(iii)血小板计数在 20×10/L 至 50×10/L(非肝活检)和 40×10/L 至 60×10/L(肝活检)之间;和(iv)拟行有创操作。肝活检患儿采用分层随机化。随机分为 ROTEM 组和常规组的患儿根据预设标准接受血液成分输血。
共筛选了 423 例有创操作,其中 60 例随机分组(每组 30 例,基线参数相似)。与常规组相比,ROTEM 组输注的总血液成分、新鲜冷冻血浆(FFP)和血小板量显著降低。ROTEM 组仅 46.7%的患儿输注血液成分,而常规组为 100%(p<0.001)。接受 ROTEM 指导输血的患儿中,FFP 的需求(ROTEM:43.3%,常规:83.3%,p=0.001)显著降低。两组患儿的操作相关出血和输血相关并发症无差异。尽管检测费用增加,但 ROTEM 的输血策略具有成本效益(p=0.002)。
在接受有创操作的肝硬化儿童中,基于 ROTEM 的输血策略可降低血液成分输注量,而不会增加操作相关出血的风险。ROTEM 指导输血策略具有成本效益。